Abstract
Regulatory agencies in both the United States and Europe are soon expected to green-light the first two antiviral drugs specifically developed to treat chronic hepatitis C, a treacherous infection that can cause cirrhosis of the liver and liver cancer, often decades after infection occurs.
Publisher
American Association for the Advancement of Science (AAAS)
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献